KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Clover Health Investments (CLOV) Current Deferred Revenue (2022 - 2024)

Clover Health Investments (CLOV) has disclosed Current Deferred Revenue for 3 consecutive years, with $17000.0 as the latest value for Q3 2024.

  • For the quarter ending Q3 2024, Current Deferred Revenue fell 99.98% year-over-year to $17000.0, compared with a TTM value of $17000.0 through Sep 2024, down 99.98%, and an annual FY2023 reading of $3.1 million, changed N/A over the prior year.
  • Current Deferred Revenue was $17000.0 for Q3 2024 at Clover Health Investments, up from $13000.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $113.5 million in Q2 2023 and bottomed at $13000.0 in Q2 2024.
  • Average Current Deferred Revenue over 3 years is $60.6 million, with a median of $96.4 million recorded in 2022.
  • The sharpest move saw Current Deferred Revenue rose 7.2% in 2023, then plummeted 99.99% in 2024.
  • Year by year, Current Deferred Revenue stood at $96.4 million in 2022, then tumbled by 96.78% to $3.1 million in 2023, then plummeted by 99.45% to $17000.0 in 2024.
  • Business Quant data shows Current Deferred Revenue for CLOV at $17000.0 in Q3 2024, $13000.0 in Q2 2024, and $3.1 million in Q4 2023.